Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Terbinafine and griseofulvin: Terbinafine 6 mg/kg/day (maximum 500 mg/day) once daily, and griseofulvin 10 mg/kg/day in 2 divided doses, both to be given orally, till cure or 8 weeks wh
Sponsors
Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with clinical diagnosis of tinea corporis, tinea cruris or tinea faciei or a combination of these conditions 2. Microscopic confirmation of diagnosis
Exclusion criteria
Exclusion criteria: (a) pregnancy (b) lactation (c) tinea elsewhere, eg, onychomycosis (d) another skin disease at the same site (e) inability to come for follow up (f) intake of terbinafine or griseofulvin in past 1 month (g) history of allergy to terbinafine or griseofulvin (h) present history of liver, renal or ischemic heart disease (i) patients on treatment with drugs that have interaction with terbinafine or griseofulvin (j) patient requiring antihistamines due to co-existing skin diseases as urticaria (k) abnormal CBC (Hb (l) patients on treatment from skin OPD who is satisfied with the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Complete clearance of skin lesions (scaling, erythema) 2. Negative KOH smearTimepoint: 2, 4, 6, 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Itching severity Timepoint: 2, 4, 6, 8 weeks | — |
Countries
India
Contacts
Public ContactVinayak N Anchan
Banaras Hindu University
Outcome results
None listed